| € millions | ||||
|---|---|---|---|---|
| 31 December 2024 | Level 1 | Level 2 | Level 3 | Total fair value |
| ASSETS AT FAIR VALUE | ASSETS AT FAIR VALUE
|
ASSETS AT FAIR VALUE
|
ASSETS AT FAIR VALUE
|
ASSETS AT FAIR VALUE
|
| Foreign exchange derivatives | Foreign exchange derivatives
|
Foreign exchange derivatives
150.1 |
Foreign exchange derivatives
|
Foreign exchange derivatives
150.1 |
| Sanofi shares | Sanofi shares
11,082.6 |
Sanofi shares
|
Sanofi shares
|
Sanofi shares
11,082.6 |
| Galderma shares | Galderma shares
2,550.0 |
Galderma shares
|
Galderma shares
|
Galderma shares
2,550.0 |
| Other securities | Other securities
23.2 |
Other securities
|
Other securities
554.6 |
Other securities
577.8 |
| Marketable securities | Marketable securities
1,829.3 |
Marketable securities
|
Marketable securities
|
Marketable securities
1,829.3 |
| TOTAL ASSETS AT FAIR VALUE | TOTAL ASSETS AT FAIR VALUE
15,485.1 |
TOTAL ASSETS AT FAIR VALUE
150.1 |
TOTAL ASSETS AT FAIR VALUE
554.6 |
TOTAL ASSETS AT FAIR VALUE
16,189.8 |
| LIABILITIES AT FAIR VALUE | LIABILITIES AT FAIR VALUE
|
LIABILITIES AT FAIR VALUE
|
LIABILITIES AT FAIR VALUE
|
LIABILITIES AT FAIR VALUE
|
| Foreign exchange derivatives | Foreign exchange derivatives
|
Foreign exchange derivatives
232.2 |
Foreign exchange derivatives
|
Foreign exchange derivatives
232.2 |
| TOTAL LIABILITIES AT FAIR VALUE | TOTAL LIABILITIES AT FAIR VALUE — |
TOTAL LIABILITIES AT FAIR VALUE
232.2 |
TOTAL LIABILITIES AT FAIR VALUE — |
TOTAL LIABILITIES AT FAIR VALUE
232.2 |
| € millions | ||||
|---|---|---|---|---|
| 31 December 2023 | Level 1 | Level 2 | Level 3 | Total fair value |
| ASSETS AT FAIR VALUE | ASSETS AT FAIR VALUE
|
ASSETS AT FAIR VALUE
|
ASSETS AT FAIR VALUE
|
ASSETS AT FAIR VALUE
|
| Foreign exchange derivatives | Foreign exchange derivatives
|
Foreign exchange derivatives
177.7 |
Foreign exchange derivatives
|
Foreign exchange derivatives
177.7 |
| Sanofi shares | Sanofi shares
10,612.1 |
Sanofi shares
|
Sanofi shares
|
Sanofi shares
10,612.1 |
| Other securities | Other securities
60.8 |
Other securities
|
Other securities
457.3 |
Other securities
518.1 |
| Marketable securities | Marketable securities
624.1 |
Marketable securities
|
Marketable securities
|
Marketable securities
624.1 |
| TOTAL ASSETS AT FAIR VALUE | TOTAL ASSETS AT FAIR VALUE
11,297.0 |
TOTAL ASSETS AT FAIR VALUE
177.7 |
TOTAL ASSETS AT FAIR VALUE
457.3 |
TOTAL ASSETS AT FAIR VALUE
11,932.0 |
| LIABILITIES AT FAIR VALUE | LIABILITIES AT FAIR VALUE
|
LIABILITIES AT FAIR VALUE
|
LIABILITIES AT FAIR VALUE
|
LIABILITIES AT FAIR VALUE
|
| Foreign exchange derivatives | Foreign exchange derivatives
|
Foreign exchange derivatives
127.1 |
Foreign exchange derivatives
|
Foreign exchange derivatives
127.1 |
| TOTAL LIABILITIES AT FAIR VALUE | TOTAL LIABILITIES AT FAIR VALUE — |
TOTAL LIABILITIES AT FAIR VALUE
127.1 |
TOTAL LIABILITIES AT FAIR VALUE — |
TOTAL LIABILITIES AT FAIR VALUE
127.1 |
Financial assets and liabilities resulting from foreign exchange and/or interest rate hedging transactions entered into with the Group’s counterparty banks are not offset in the balance sheet since they are FBF (French Banking Federation) or ISDA (International Swaps and Derivatives Association) agreements that only provide for offsetting in the event of default by one of the parties to the agreement. Accordingly, they do not meet the offsetting criteria set out in IAS 32.
Had the agreements been offset at the level of each counterparty bank, assets and liabilities would have decreased by €136.4 million, €137.8 million and €105.5 million respectively in 2025, 2024 and 2023.
Share capital consists of 533,783,028 shares with a par value of €0.20 at 31 December 2025 following the issue of 279,923 shares for the employee shareholding plan and 547,720 free shares and the cancellation of 1,356,636 shares.
Share capital consisted of 534,312,021 shares with a par value of €0.20 at 31 December 2024 following the issue of 230,423 shares for the employee shareholding plan and 664,680 free shares and the cancellation of 1,308,557 shares.
Share capital consisted of 534,725,475 shares with a par value of €0.20 at 31 December 2023, following the issue of 34,020 shares for the employee shareholding plan and 776,525 free shares and the cancellation of 1,271,632 shares.
Treasury shares are recorded at acquisition cost and deducted from equity. Capital gains/losses on disposal of these items net of tax are charged directly to equity and do not contribute to profit for the financial year.